Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Willemze, R ^a   Dreyling, M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CD30 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; INTERFERON; METHOTREXATE; PREDNISOLONE; PREDNISONE; PSORALEN DERIVATIVE; RETINOID; RITUXIMAB; STEROID; VINCRISTINE; VORINOSTAT;

ADJUVANT THERAPY; ARTICLE; B CELL LYMPHOMA; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EVALUATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; MYCOSIS FUNGOIDES; NK T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PUVA; SEZARY SYNDROME; SKIN LYMPHOMA; SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA; T CELL LYMPHOMA;

EUROPE; HEALTH PLANNING GUIDELINES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549100195     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp147     Document Type: Article

References (11)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Olsen EA, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Study Group of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
3. Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome. A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Study Group of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
4. Kaye FJ, Bunn PA, Steinberg SM et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 784-790.
5. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-1107.
6. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030.
7. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.
8. Bekkenk M, Geelen FAMJ, van Voorst Vader PC et al. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: Long term follow-up data of 219 patients and guidelines for diagnosis and treatment. A report from the Dutch Cutaneous Lymphoma Group. Blood 2000; 95: 3653-3661.
9. Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification and prognostic factors. An EORTC Cutaneous Lymphoma Group study of 83 cases. Blood 2008; 111: 838-845.
10. Senff NJ, Noordijk EM, Kim YH et al. EORTC/ISCL consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-1609.
11. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.